EF Hutton Initiates Coverage On Kairos Pharma with Buy Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on Kairos Pharma with a Buy rating and set a price target of $9.
October 14, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton has initiated coverage on Kairos Pharma with a Buy rating and a price target of $9, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $9 by EF Hutton suggests a positive sentiment towards Kairos Pharma. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100